AIA Group’s Haemonetics HAE Stock Holding History

AIA Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,996	Closed	-$255K	–	303
2023 Q2	$255K	Buy	+2,996	New	+$253K	0.01%	295

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

AIA Group's HAE Position: Q3 2023 in Review

AIA Group sold out of Haemonetics (HAE) in Q3 2023, closing a stake of 2,996 shares — an estimated $255K sold.

AIA Group first reported a position in HAE in Q2 2023 and held it in 1 quarter. The position peaked at $255K in Q2 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q3 2023.

AIA Group reported no remaining Haemonetics position as of Q3 2023 after selling out during the quarter.
AIA Group sold 2,996 Haemonetics shares in Q3 2023, an estimated $255K.
AIA Group first reported a position in Haemonetics in Q2 2023 and held it in 1 quarter.
AIA Group's Haemonetics position peaked at $255K in Q2 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q3 2023.

Based on AIA Group's 13F filing for Q3 2023, filed 1 Nov 2023.